Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and

Related Experiment Video

Updated: Dec 13, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Jiasheng Wang1, Yeseong Kim2

  • 1Department of Internal Medicine, MetroHealth Medical Center, Case Western Reserve University, 2500 MetroHealth Dr, Cleveland, OH, 44109, USA. jwang1@metrohealth.org.

International Journal of Hematology
|July 26, 2020
PubMed
Abstract

Insights

Daratumumab treatment in multiple myeloma patients shows a reduced risk of venous thromboembolism (VTE). Arterial thromboembolism (ATE) risk remained unchanged, with a slight trend towards higher thrombocytopenia.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Multiple myeloma (MM) patients face elevated risks of venous thromboembolism (VTE) and arterial thromboembolism (ATE).
  • Thrombosis risk varies significantly across different MM treatment regimens.
  • The impact of daratumumab on thrombosis risk in MM is not well-established.

Purpose of the Study:

  • To evaluate the effect of daratumumab on the risk of VTE and ATE in patients with multiple myeloma.
  • To assess the association between daratumumab and other adverse events, including thrombocytopenia and gastrointestinal bleeding.

Main Methods:

  • A systematic literature search was performed up to April 2020.
  • Data on VTE (pulmonary embolism, deep venous thrombosis) and ATE (ischemic stroke, myocardial infarction) were extracted from six clinical trials.
  • Incidence of thrombocytopenia and gastrointestinal bleeding was also analyzed.

Main Results:

  • Daratumumab use was linked to a significantly lower risk of VTE compared to non-daratumumab regimens (RR, 0.60; 95% CI, 0.40-0.91).
  • No significant difference in ATE risk was observed between groups (RR, 0.80; 95% CI, 0.48-1.33).
  • A trend towards increased Grade 3/4 thrombocytopenia was noted with daratumumab (RR, 1.14; 95% CI, 0.94-1.38), while GI bleeding risk was not significantly different.

Conclusions:

  • Daratumumab is associated with a reduced risk of venous thromboembolism in clinical trials involving multiple myeloma patients.
  • The study did not find a significant impact of daratumumab on arterial thromboembolism risk.
Keywords:
Arterial thromboembolismDaratumumabMultiple myelomaVenous thromboembolism

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.7K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.0K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
184
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
108
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
200
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
135
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
157